The role of antiplatelet therapy in the management of acute coronary syndromes

Bibliography

• ANTIPLATELET TRIALISTS' COLLABORATION: Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308(6921):81–106.
   PubMed Web of Science ®Google Scholar
• ••Use of antiplatelet regimens resulted in a one third reduction in nonfatal MI accompanied by a nonsignificant increase in stroke. The absolute reduction in events was smaller in high-risk patients despite a longer period of treatment.
   Google Scholar
• THE RISC GROUP: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet (1990) 336(8719):827–830.
   PubMed Web of Science ®Google Scholar
• LEWIS HD, Jr., DAVIS JW, ARCHIBALD DG et al Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl. J. Med. (1983) 309(7):396–403.
   Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. (1997) 336(24):1689–1696.
   PubMed Web of Science ®Google Scholar
• THE CAPTURE STUDY INVESITAGORS: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349(9063):1429–1435.
   PubMed Web of Science ®Google Scholar
• PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT (PRISM) STUDY INVESTIGATORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl. Med. (1998) 338(20:1498–1505.
   PubMedGoogle Scholar
• PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT IN PATIENTS LIMITED BY UNSTABLE SIGNS AND SYMPTOMS (PRISM-PLUS) STUDY INVESTIGATORS: Inhibition of the platelet glycoprotein IIb/ IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl. I Med. (1998) 338(21):1488–1497.
   PubMed Web of Science ®Google Scholar
• •Tirofiban, when administered with heparin and aspirin, was associated with a lower incidence of ischaemic events in patients with ACS as compared with patients who received heparin and aspirin alone.
   Google Scholar
• THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoproteinin UnstableAngina: Receptor Suppression Using Integrilin Therapy. N Engl. I Med. (1998) 339(7):436–443.
   Google Scholar
• THE RANDOMIZED EFFICACY STUDY OF TIROFIBAN FOR OUTCOMES AND RESTENOSIS (RESTORE) INVESTIGATORS: Effects of platelet glycoprotein blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation (1997) 96(5):1445–1453.
   PubMed Web of Science ®Google Scholar
• THE EPISTENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet (1998) 352(9122):87–92.
   PubMed Web of Science ®Google Scholar
• BERTRAND ME, RUPPRECHT HJ, URBAN P, GERSHLICK AH: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation (2000) 102(6):624–629.
   PubMed Web of Science ®Google Scholar
• •Clopidogrel and ticlopidine have comparable efficacy with regard to cardiac events after successful stenting.
   Google Scholar
• YUSUF S, ZHAO F, MEHTA SR, CHROLAVICIUS S, TOGNONI G, FOX KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345(7):494–502.
   PubMed Web of Science ®Google Scholar
• ••A large multicentred trial demonstratingthat clopidogrel has beneficial effects in patients with non-ST segment elevation ACS.
   Google Scholar
• MICHELSON AD: How platelets work: platelet function and dysfunction. Thromb. Thrombolysis (2003) 16(1-2):7–12.
   PubMed Web of Science ®Google Scholar
• BECKER RC: Platelet surface physiology and its importance in pharmacotherapy design and development: the adenosine diphosphate receptor antagonists. Thromb. Thrombolysis (2000) 10(1):35–53.
   PubMed Web of Science ®Google Scholar
• BATES SM, WEITZ JI: Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. Cardiovasc. Res. (1999) 41(2):418–432.
   PubMed Web of Science ®Google Scholar
• THEROUX P, FUSTER V: Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation (1998) 97(12):1195–1206.
   PubMed Web of Science ®Google Scholar
• •An excellent review of the pathophysiology of ACS.
   Google Scholar
• PATRONO C: Aspirin as an antiplatelet drug. N Engl. I Med. (1994) 330(18):1287–1294.
   PubMed Web of Science ®Google Scholar
• ISIS-2 (SECOND INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.I Am. Coll. Cardiol (1988) 12(6 Suppl. A):3A–13A.
   Google Scholar
• TAYLOR DW, BARNETT HJ, HAYNES RB et al: Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet (1999) 353(9171):2179–2184.
   PubMed Web of Science ®Google Scholar
• ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMI (2002) 324(7329):71–86.
   PubMed Web of Science ®Google Scholar
• VAN HECKEN A, JULIANO ML, DEPRE M et al.: Effects of enteric-coated, low-dose aspirin on parameters of platelet function. Ailment. Pharmacol Ther. (2002) 16(9):1683–1688.
   PubMed Web of Science ®Google Scholar
• VOLTURO GA, AGHABABIAN RV: Facilitating optimal care of acute coronary, cerebrovascular and peripheral vascular syndromes in the emergency department: the role of oral antiplate therapy. I Thromb. Thrombolysis (2004) 17(1):29–34.
   PubMed Web of Science ®Google Scholar
• GUM PA, KOTTKE-MARCHANT K, WELSH PA, WHITE J, TOPOL EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol (2003) 41(6):961–965.
   PubMed Web of Science ®Google Scholar
• •There is a greater than threefold increase in the risk of major adverse events associated with aspirin resistance.
   Google Scholar
• CHEN WH, LEE PY, NG W, TSE HF, LAU CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. I Am. Coll. Cardiol (2004) 43(6):1122–1126.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM, COHEN M, BERNINK PJ et al.: The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 284(7):835–842.
   PubMed Web of Science ®Google Scholar
• ALEXANDER JH, HARRINGTON RA, TUTTLE RH et al: Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am. Cardiol (1999) 83(8):1147–1151.
   Google Scholar
• BHATT DL: Aspirin resistance: more thanjust a laboratory curiosity. I Am. Coll. Cardiol (2004) 43(6):1127–1129.
   PubMed Web of Science ®Google Scholar
• FITZGERALD GA: Dipyridamole. N. Engl. J. Med. (1987) 316(20):1247–1257.
   Google Scholar
• MULLER TH, SU CA, WEISENBERGER H, BRICKL R, NEHMIZ G, EISERT WG: Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. BE J. Clin. Pharmacol (1990) 30(2):179–186.
   PubMed Web of Science ®Google Scholar
• DIENER HC, CUNHA L, FORBES C, SIVENIUS J, SMETS P, LOWENTHAL A: European Stroke Prevention Study. 2.Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol Sci. (1996) 143(1–2):1–13.
   Google Scholar
• PATRONO C, COLLER B, DALEN JE et al: Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 119\(Supp1.1):39S–63S.
   Google Scholar
• AMBROSE JA: Plaque disruption and the acute coronary syndromes of unstable angina and myocardial infarction: if the substrate is similar, why is the clinical presentation different?" Am. Coll. Cardiol (1992) 19(7):1653–1658.
   PubMed Web of Science ®Google Scholar
• STEINHUBL SR, BERGER PB, MANN JT et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 288(19):2411–2420.
   PubMed Web of Science ®Google Scholar
• •Long-term (up to 1 year) antiplatelet therapy with clopidogrel significantly reduced the risk of ischaemic events. A clopidogrel loading dose given within 3 hours of the procedure did not reduce events at 28 days; however, subgroup analysis suggests that a longer time interval between the clopidogrel loading dose and PCI may reduce recurrent cardiovascular events.
   Google Scholar
• SCHOMIG A, NEUMANN FJ, KASTRATI A et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl. J. Med. (1996) 334(17):1084–1089.
   PubMed Web of Science ®Google Scholar
• BERTRAND ME, LEGRAND V, BOLAND J et al: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation (1998) 98(16):1597–1603.
   PubMed Web of Science ®Google Scholar
• MUELLER C, ROSKAMM H, NEUMANN FJ et al: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J. Am. Coll. Cardiol (2003) 41(6):969–973.
   PubMed Web of Science ®Google Scholar
• BHATT DL, BERTRAND ME, BERGER PB et al: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol (2002) 39(1):9–14.
   PubMed Web of Science ®Google Scholar
• SAVI P, NURDEN P, NURDEN AT: Clopidogrel: A review of its mechanism of action. Platelets (1998) 9:251–255.
   PubMed Web of Science ®Google Scholar
• CAPRIE SC: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 348(9038):1329–1339.
   PubMed Web of Science ®Google Scholar
• •Long-term administration of clopidogrel to patients with atherosclerotic disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, MI or vascular death. The overall safety of clopidogrel is as good as that of medium-dose aspirin.
   Google Scholar
• CADROY Y, BOSSAVY JP, THALAMAS C, SAGNARD L, SAKARIASSEN K, BONEU B: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation (2000) 101(202823–2828.
   Google Scholar
• GENT M: Benefit of Clodogrel in patients with coronary disease. Circulation (1997) 96:1467 (abstract).
   Google Scholar
• HARKER LA, MARZEC UM, KELLY AB et al: Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation (1998) 98(22):2461–2469.
   PubMed Web of Science ®Google Scholar
• MAKKAR RR, EIGLER NL, KAUL S et al: Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur. Heart J. (1998) 19(10):1538–1546.
   PubMed Web of Science ®Google Scholar
• BUDAJ A, YUSUF S, MEHTA SR et al: Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 106(13):1622–1626.
   PubMed Web of Science ®Google Scholar
• HIRSH J, BHATT DL: Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch. Intern. Med. (2004) 164(19):2106–2110.
   PubMed Web of Science ®Google Scholar
• •High-risk subgroups of patients who were enrolled in the CURE and CAPRIE trials derived more beneficial effects from clopidogrel therapy as compared with the study population as a whole.
   Google Scholar
• MEHTA SR, YUSUF S, PETERS RJ et al: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358(9281):527–533.
   PubMed Web of Science ®Google Scholar
• BRAUNWALD E, ANTMAN EM, BEASLEY JW et al: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol (2002) 40(7):1366–1374.
   PubMed Web of Science ®Google Scholar
• ••The most recent evidence-based andweighted guidelines for the management of patients with ACS.
   Google Scholar
• GURBEL PA, BLIDEN KP, HIATT BL, O'CONNOR CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 107(23):2908–2913.
   PubMed Web of Science ®Google Scholar
• MATETZKY S, SHENKMAN B, GUETTA V et al: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 109(25):3171–3175.
   PubMed Web of Science ®Google Scholar
• •Up to 25% of ST-segment elevation MI patients undergoing PCI are resistant to clopidogrel. These patients are at increase risk for recurrent cardiac events.
   Google Scholar
• SEREBRUANY VL, STEINHUBL SR, BERGER PB, MALININ Al, BHATT DL, TOPOL EJ: Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol (2005) 45(2):246–251.
   PubMed Web of Science ®Google Scholar
• BONEU B, DESTELLE G: Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb. Haemost. (1996) 76(6):939–943.
   PubMed Web of Science ®Google Scholar
• JARVIS B, SIMPSON K: Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs (2000) 60(2)347–377.
   Google Scholar
• SAVCIC M, HAUERT J, BACHMANN F, WYLD PJ, GEUDELIN B, CARIOU R: Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semi]. Thromb. Hemost. (1999) 25\(Suppl. 2):15–19.
   Google Scholar
• CHEN L, BRACEY AW, RADOVANCEVIC R et al: Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. I Thorac. Cardiovasc. Surg. (2004) 128(3):425–431.
   PubMed Web of Science ®Google Scholar
• CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation (2001) 103(2):201–206.
   PubMed Web of Science ®Google Scholar
• KLEIMAN NS, OHMAN EM, CALIFF RM et al.: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. I Am. Coll Cardiol. (1993) 22(2):381–389.
   Google Scholar
• MOSER M, BERTRAM U, PETER K, BODE C, RUEF J: Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. Cardiovasc. Pharmacol. (2003) 41(4):586–592.
   PubMed Web of Science ®Google Scholar
• WHITE HD: Unmet therapeutic needs in the management of acute ischemia. Am. J. Cardiol. (1997) 80(4A):2B–10B.
   Google Scholar
• ELLIS SG, TCHENG JE, NAVETTA Fl et al.: Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/ IIIa in patients undergoing elective coronary angioplasty. Coron. Artery Dis. (1993) 4(2):167–175.
   PubMed Web of Science ®Google Scholar
• MASCELLI MA, LANCE ET, DAMARAJU L, WAGNER CL, WEISMAN HF, JORDAN RE: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP llb/IIIa receptor blockade. Circulation (1998) 97(17):1680–1688.
   PubMed Web of Science ®Google Scholar
• TCHENG JE, ELLIS SG, GEORGE BS et al.: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation (1994) 90(4):1757–1764.
   PubMed Web of Science ®Google Scholar
• MADAN M, BERKOWITZ SD, TCHENG JE: Glycoprotein IIb/IIIa integrin blockade. Circulation (1998) 98(23):2629–2635.
   PubMed Web of Science ®Google Scholar
• KNIGHT DM, WAGNER C, JORDAN R et al.: The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol. Immunol. (1995) 32(16):1271–1281.
   PubMed Web of Science ®Google Scholar
• TCHENG JE: Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am. I Cardiol (1996) 78(3A):35–40.
   Google Scholar
• TAM SH, SASSOLI PM, JORDAN RE, NAKADA MT: Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation (1998) 98(10:1085–1091.
   PubMedGoogle Scholar
• COLLER BS: Potential non-glycoprotein IIb/IIIa effects of abciximab. Am. Heart! (1999) 138(1 Pt 2):S1–55.
   Google Scholar
• THE EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl. J. Med. (1994) 330(14):956–961.
   PubMed Web of Science ®Google Scholar
• SIMOONS ML: Effect of glycoprotein IIb/ IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet (2001) 357(9272):1915–1924.
   PubMed Web of Science ®Google Scholar
• ••Abciximab is not beneficial as a first linemedical therapy in patients with ACS who were not undergoing early revascularisation.
   Google Scholar
• SCARBOROUGH RM, Rose JW, Naughton MA et al.: Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J. Biol. Chem. (1993) 268(2):1058–1065.
   PubMed Web of Science ®Google Scholar
• KLEIMAN NS: Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am. Heart! (1999) 138(4 Pt 2):263–275.
   Google Scholar
• IMPACT-II: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet (1997) 349(9063):1422–1428.
   Google Scholar
• THE ESPRIT INVESTIGATOR: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 356(9247):2037–2044.
   PubMed Web of Science ®Google Scholar
• TCHENG JE, TALLEY JD, O'SHEA JCet al: Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am. Cardiol (2001) 88(10):1097–1102.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, MOLITERNO DJ, HERRMANN HC et al: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl. J. Med. (2001) 344(25):1888–1894.
   PubMed Web of Science ®Google Scholar
• •In the setting of PCI, tirofiban offered less protection from ischaemic events than did abciximab.
   Google Scholar
• OHMAN EM, KLEIMAN NS, GACIOCH G et al: Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation (1997) 95(4):846–854.
   Google Scholar
• TOPOL EJ: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein inhibition: the GUSTO V randomised trial. Lancet (2001) 357(9272):1905–1914.
   PubMed Web of Science ®Google Scholar
• THE ASSENT INVESTIGATORS: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358(9282):605–613.
   PubMed Web of Science ®Google Scholar
• ••The combination of tenecteplaseand abciximab resulted in more bleeding complications and higher mortality than the combination of tenecteplase and enoxaparin for the medical management of ST-segment elevation MI.
   Google Scholar
• LINCOFF AM, CALIFF RM, VAN DE WERF F et al: Mortality at 1 year with combination platelet glycoprotein IIb/ Ma inhibition and reduced-dose fibrinolytic therapy versus conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA (2002) 288(17):2130–2135.
   PubMed Web of Science ®Google Scholar
• THE PARADIGM INVESTIGATORS: Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. I. Am. Coll. Cardiol (1998) 32(7):2003–2010.
   PubMed Web of Science ®Google Scholar
• STRATEGIES FOR PATENCY ENHANCEMENT IN THE EMERGENCY DEPARTMENT (SPEED) GROUP: Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation (2000) 101(24):2788–2794.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM, GIUGLIANO RP GIBSON CM et al: Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 99(20:2720–2732.
   Google Scholar
• DALBY M, MONTALESCOT G, BAL DIT SOLLIER C et al.: Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J. Am. Coll. Cardiol (2004) 43(2):162–168.
   Google Scholar
• ••Eptifibatide provides significant potentantiplatelet activity above aspirin and clopidogrel suggesting an additive and Immediate protection in the management of patients with non-ST-segment elevation MI.
   Google Scholar
• ANGIOLILLO DJ, FERNANDEZ-ORTIZ A, BERNARDO E et al: High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart' (2004) 25(20:1903–1910.
   PubMedGoogle Scholar
• KASTRATI A, VON BECKERATH N, JOOST A, POGATSA-MURRAY G, GORCHAKOVA 0, SCHOMIG A: Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation (2004) 110(14):1916–1919.
   PubMed Web of Science ®Google Scholar
• DE LA CRUZ JP, ARREBOLA MM, VILLALOBOS MA et al: Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. Eur. Pharmacol (2004) 484(1):19–27.
   PubMed Web of Science ®Google Scholar
• BHATT DL, TOPOL EJ: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am. Heart J. (2004) 148(2):263–268.
   PubMed Web of Science ®Google Scholar
• KASTRATI A, MEHILLI J, SCHUHLEN H et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl. J. Med. (2004) 50(3):232–238.
   Google Scholar
• SABATINE MS, CANNON CP, GIBSON CM et al: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl. I Med. (2005) 352(12):1179–1189.
   PubMed Web of Science ®Google Scholar
• RODERICK PJ, WILKES HC, MEADE TW: The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. BE J. Pharmacol (1993) 35(3):219–226.
   Web of Science ®Google Scholar
• CHAN FK, CHING JY, HUNG LC et al: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl. J. Med. (2005) 352(3):238–244.
   PubMed Web of Science ®Google Scholar
• CURTIN R, FOX D, FITZGERAL D: In: Clopidogrel and Ticlopidine. Michelson AD, (Ed.) Platelets. San Diego: Academic Press; 2002.
   Google Scholar
• LAU WC, WASKELL LA, WATKINS PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 107(0:32–37.
   PubMedGoogle Scholar
• SEREBRUANY VL, MIDEI MG, MALININ Al et al.: Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch. Intern. Med. (2004) 164(18):2051–2057.
   PubMed Web of Science ®Google Scholar
• SAW J, STEINHUBL SR, BERGER PBet al.: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 108(8):921–924.
   Google Scholar
• BERKOWITZ SD, SANE DC, SIGMON KN et al: Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J. Am. Coll. Cardiol (1998) 32(2):311–319.
   Google Scholar
• TCHENG JE, KEREIAKES DJ, LINCOFF AM et al: Abciximab readministration: results of the ReoPro Readministration Registry. Circulation (2001) 104(8):870–875.
   PubMed Web of Science ®Google Scholar